Matthias Kromayer
Chief Executive Officer at Tavia Consulting GmbH
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Harpreet Singh-Jasuja | M | 50 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 9 years |
Michael Motschmann | M | 67 |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 10 years |
Rainer Kramer | M | 60 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 2 years |
Philipp Beckhove | M | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 8 years |
Wulf Fischer-Knuppertz | M | - |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | 11 years |
Henrijette Richter | M | 53 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | - |
Toni Weinschenk | M | 51 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 9 years |
Jürgen Kosch | M | 57 |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 20 years |
Steffen Walter | M | 47 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 9 years |
Moritz Seuster | M | - |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | - |
Anna Carina Eichhorn | M | 52 | 7 years | |
Patrick Baeuerle | M | 66 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 8 years |
Apollon Papadimitriou | M | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 7 years |
Ulrich Scherbel | M | - |
AMSilk GmbH
AMSilk GmbH TextilesProcess Industries AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany. | 4 years |
Klaus Feix | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | - |
Carsten Reinhardt | M | 57 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Hans-Jochem Kolb | M | - |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Soeren Hein | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 7 years |
Kristian Schmidt-Garve | M | 53 |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 17 years |
Fadi Abdi | M | - |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | - |
Axel Thierauf | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 16 years |
Boris Bernstein | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | 6 years |
Gerald Heinz Möller | M | 80 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 4 years |
Siegfried Winkelbeiner | M | - |
AMSilk GmbH
AMSilk GmbH TextilesProcess Industries AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany. | - |
Erich Schlick | M | 72 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Friedrich von Bohlen und Halbach | M | 61 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Manfred Rüdiger | M | 59 |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Klaus Schollmeier | M | 67 |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Heather Mason | F | 63 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Wolfgang Colberg | M | 64 |
AMSilk GmbH
AMSilk GmbH TextilesProcess Industries AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany. | 9 years |
Rainer Strohmenger | M | 57 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 4 years |
Matthias Guth | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | - |
Nicolas Schauer | M | 48 |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | - |
Özlem Türeci | M | 57 |
Ci3 Management UG
| - |
Christoph Huber | M | 80 |
Ci3 Management UG
| - |
Christof Hettich | M | 64 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Michael Burgess | M | 61 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 2 years |
Peter Chambré | M | 68 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 12 years |
Harald F. Stock | M | 56 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Alexander Pelzer | M | 38 | 10 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Georg Kellinghusen | M | 77 | 8 years | |
Holger Zinke | M | 61 | 24 years | |
Siegfried L. Drüker | M | 72 | 5 years | |
Thomas Kessler | M | 59 | - | |
Cecil Motschmann | M | - |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | - |
Ludger Müller | M | 76 | - | |
Martin B. Jager | M | 61 | 3 years | |
Christian Körfgen | M | 59 | 3 years | |
Henricus Cornelis Marks | M | 63 | 1 years | |
Thomas Deichmann | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 36 | 72.00% |
United States | 11 | 22.00% |
Austria | 4 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Matthias Kromayer
- Personal Network